A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- Registry ID
- EUCTR2006-004571-36
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Cougar Biotechnology, Inc
- Start date
- 2006-10-19
- Completion date
- 2008-07-25
- Last update
- 2026-08-16
Conditions
- Hormone refractory prostate cancer
Summary
To evaluate the anti-tumor effects of CB7630 in patients with androgen independent metastatic prostate cancer (AIPC) who have failed docetaxel based chemotherapy, as measured by the proportion of patients achieving a PSA decline of >50% (PSA response) according to Prostate-Specific Antigen Working Group (PSAWG) criteria
Locations
View on source registry